EPCAM and cancer: This result suggests that although EMT seem to occur in tumor tissue, cancer cells preserve epithelial marker expression, which is consistent with the result of Pirozzi et al., who demonstrated coexpression of EpCAM and mesenchymal marker CD90 in approximately 10% of primary tumor cells of NSCLC patients [34].